TO: Physicians, other Healthcare Providers, and Laboratories

Please distribute a copy of this information to each provider in your organization.

Questions regarding this information may be directed to the following Region IV health officers:

Alan Melnick, MD, MPH, CPH
Clark County Public Health, (360) 397-8412

Jennifer Vines, MD, MPH
Cowlitz County Health & Human Services, (360) 414-5599
Wahkiakum County Health & Human Services, (360) 795-6207

Alert categories:

**Health Alert**: conveys the highest level of importance; warrants immediate action or attention.

**Health Advisory**: provides important information for a specific incident or situation; may not require immediate action.

**Health Update**: provides updated information regarding an incident or situation; no immediate action necessary.
To ensure continued testing availability for the highest risk patients and for patients for whom cost is a barrier to testing, testing for Zika virus at Washington State Public Health Laboratories is now limited to:

- Patients for whom cost is a barrier to testing
- Infants with possible congenital exposure to Zika virus

**CDC Zika testing criteria must be met.** Testing pre-approval from the local health jurisdiction will continue to be required for these individuals. All infant testing should continue to be performed by PHL.

All other individuals should be tested using the normal mechanism for obtaining clinical commercial laboratory testing and following the CDC testing algorithm, with the exception of infant testing.

- Local health jurisdiction approval and notification are not required for commercial testing
- Zika virus testing is available through many commercial laboratories, including LabCorp, ARUP, Quest, and Mayo (see attached list).
- Public Health is available for consultation about determining whether possible Zika virus exposure occurred, choosing the correct testing algorithm, and following up with patients who test positive.

**Report suspected Zika virus cases by calling your local health department:**

- Clark County Public Health: (360) 397-8182
- Cowlitz County Health Department: (360) 414-5599
- Skamania County Community Health: (509) 427-3850
- Wahkiakum County Health and Human Services: (360) 795-6207

**Important Reminders:**

- Counsel women who are pregnant or planning to become pregnant to avoid travel to areas with Zika virus transmission risk and to avoid unprotected sex with sexual partners who have traveled to areas with CDC Zika travel notices
- Assess all pregnant women for possible Zika virus exposure at each prenatal care visit. Record travel history and sexual partner travel history at every visit and counsel pregnant women about the risk of Zika virus infection.
• Test every pregnant patient with possible exposure to Zika virus from:
  o Travel to an area with a CDC Zika travel notice, unprotected sex with someone who traveled to an area with a CDC Zika travel notice, or travel to another area with possible Zika transmission risk and development of symptoms consistent with Zika virus disease within 14 days
• Counsel women with possible Zika virus exposure to wait at least 8 weeks before trying to conceive, or at least 6 months if their male partner also had possible exposure to Zika virus

Resources

DOH Zika webpage for Healthcare Providers: http://www.doh.wa.gov/YouandYourFamily/IllnessandDisease/ZikaVirus/healthcareprovidersClinicallabs

Zika Virus Test Ordering Guidance

If in doubt about whether testing is indicated, or which tests to order, contact your local health department

Testing should only be ordered for persons with symptoms consistent with Zika virus disease and possible exposure, or for pregnant women with possible Zika virus exposure and their infants. Testing should not be used to rule out infection for pre-conception planning.

If a patient meets CDC testing criteria:
• In general, order both an RT-PCR or NAA (on serum and urine) and an IgM ELISA (on serum).
• As the length of time since last travel or sexual exposure or disease onset increases past 14 days, viral RNA in serum and urine declines and RT-PCR or NAA will be less useful. For patients seen >2 weeks after disease onset or last exposure, IgM ELISA should be ordered.
• For pregnant women who test negative in the first two weeks after last travel or sexual exposure, collect a second serum specimen for IgM ELISA between 2-12 weeks after last exposure
• For patients with symptoms consistent with mosquito-borne disease, dengue and chikungunya testing should also be ordered
• A negative RT-PCR or NAA test never rules out Zika virus infection; order IgM ELISA on serum
• A positive IgM ELISA is preliminary evidence of Zika virus infection that should be confirmed by PRNT testing at CDC
  o Laboratories will automatically send IgM positive, equivocal, or inconclusive specimens to CDC for PRNT testing
  o Decisions about clinical management of IgM positive patients should wait for PRNT results

To subscribe or unsubscribe from this listserv, email: Tippy.Hartford@clark.wa.gov.
• If all or part of an exposure period occurred more than 12 weeks prior to specimen collection, infection in asymptomatic pregnant women cannot be ruled out. Contact your local health department about testing at birth.
• For infant testing or testing at the time of delivery, contact your local health department.

Contact your local health department at the following numbers:

- Clark County Public Health: (360) 397-8182
- Cowlitz County Health Department: (360) 414-5599
- Skamania County Community Health: (509) 427-3850
- Wahkiakum County Health and Human Services: (360) 795-6207

Thank you for your partnership.

To subscribe or unsubscribe from this listserv, email: Tippy.Hartford@clark.wa.gov.
1. Zika Virus Antibody (IgM), MAC-ELISA
   Testing should only be performed on individuals meeting Centers for Disease Control and Prevention (CDC) Zika virus clinical criteria (e.g., clinical signs and symptoms associated with Zika virus infection) and/or CDC …… More

2. Zika Virus RNA, Qualitative, Real-Time RT-PCR
   Testing should only be performed on individuals meeting Centers for Disease Control and Prevention (CDC) Zika virus clinical criteria (e.g., clinical signs and symptoms associated with Zika virus infection) and/or CDC …… More

3. Zika Virus RNA, Qualitative, Real-Time RT-PCR Panel, Serum/Urine
   Testing should only be performed on individuals meeting Centers for Disease Control and Prevention (CDC) Zika virus clinical criteria (e.g., clinical signs and symptoms associated with Zika virus infection) and/or CDC …… More

2 results for “zika”

<table>
<thead>
<tr>
<th>Number</th>
<th>Name</th>
<th>Specimen</th>
<th>New or Updated</th>
</tr>
</thead>
<tbody>
<tr>
<td>163049</td>
<td>Zika Virus, MAC-ELISA, IgM, Serum</td>
<td>Serum</td>
<td></td>
</tr>
<tr>
<td>139600</td>
<td>Zika Virus Comprehensive Profile, NAA, Serum and Urine</td>
<td>Serum, frozen or refrigerated, ...</td>
<td></td>
</tr>
</tbody>
</table>
2014065  **Zika Virus by PCR, Blood**

**Ordering Recommendation:**

Testing should only be performed on individuals meeting Centers for Disease Control and Prevention (CDC) clinical criteria for Zika virus (e.g., clinical signs and symptoms associated with Zika virus infection) and/or CDC epidemiological criteria for Zika virus (e.g., history of residence in or travel to a geographic region with active Zika transmission at the time of travel, or other epidemiological criteria for which Zika virus testing may be indicated).

2014069  **Zika Virus by PCR, Urine**

**Ordering Recommendation:**

Testing should only be performed on individuals meeting Centers for Disease Control and Prevention (CDC) clinical criteria for Zika virus (e.g., clinical signs and symptoms associated with Zika virus infection) and/or CDC epidemiological criteria for Zika virus (e.g., history of residence in or travel to a geographic region with active Zika transmission at the time of travel, or other epidemiological criteria for which Zika virus testing may be indicated).

2013842  **Zika Virus IgM Antibody Capture (MAC), by ELISA**

**Ordering Recommendation:**

Use for patients whose symptoms began, or whose documented exposure occurred, at least 14 days prior to testing. Should also be used as followup for patients with negative serum and urine results from molecular testing performed less than 14 days after symptom onset.

---

### Mayo Clinic


**RZIKS - Zika Virus, PCR, Molecular Detection, Serum**

Test ID: RZIKS Zika Virus, PCR, Molecular Detection, Serum. ... Assessment for Zika Virus Infection in Nonpregnant Individuals. ...

<table>
<thead>
<tr>
<th>Overview</th>
<th>Specimen</th>
<th>Clinical and Interpretive</th>
<th>Performance</th>
<th>Fees and Coding</th>
</tr>
</thead>
</table>

**MZIKV - Zika Virus IgM Antibody Capture MAC-ELISA, Serum**

Test ID: MZIKV Zika Virus IgM Antibody Capture MAC-ELISA, Serum. ... Highlights. This assay is a screening test for IgM-class antibodies to Zika virus. ...

<table>
<thead>
<tr>
<th>Overview</th>
<th>Specimen</th>
<th>Clinical and Interpretive</th>
<th>Performance</th>
<th>Fees and Coding</th>
</tr>
</thead>
</table>

**PNZIK - Prenatal Zika Virus IgM Antibody Capture MAC-ELISA, Serum**

Test ID: PNZIK Prenatal Zika Virus IgM Antibody Capture MAC-ELISA, Serum. ... Screening for the presence of IgM-class antibodies to Zika virus. ...

<table>
<thead>
<tr>
<th>Overview</th>
<th>Specimen</th>
<th>Clinical and Interpretive</th>
<th>Performance</th>
<th>Fees and Coding</th>
</tr>
</thead>
</table>

**RZIKU - Zika Virus, PCR, Molecular Detection, Random, Urine**

Test ID: RZIKU Zika Virus, PCR, Molecular Detection, Random, Urine. ... Assessment for Zika Virus Infection in Nonpregnant Individuals. ...

<table>
<thead>
<tr>
<th>Overview</th>
<th>Specimen</th>
<th>Clinical and Interpretive</th>
<th>Performance</th>
<th>Fees and Coding</th>
</tr>
</thead>
</table>